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Background: CD86-CD28 interaction has been suggested as the principal costimulatory pathway for the activation
and differentiation of naïve T cells in allergic inflammation. However, it remains uncertain whether this pathway
also has an essential role in the effector phase. We sought to determine the contribution of CD86 on dendritic
cells in the reactivation of allergen-specific Th2 cells.
Methods: We investigated the effects of the downregulation of CD86 by short interfering RNAs (siRNAs) on
Th2 cytokine production in the effector phase in vitro and on asthma phenotypes in ovalbumin (OVA)-sensitized
and -challenged mice.
Results: Treatment of bone marrow-derived dendritic cells (BMDCs) with CD86 siRNA attenuated LPS-induced
upregulation of CD86. CD86 siRNA treatment impaired BMDCs’ ability to activate OVA-specific Th2 cells. Intratracheal
administration of CD86 siRNA during OVA challenge downregulated CD86 expression in the airway mucosa. CD86
siRNA treatment ameliorated OVA-induced airway eosinophilia, airway hyperresponsiveness, and the elevations
of OVA-specific IgE in the sera and IL-5, IL-13, and CCL17 in the bronchoalveolar lavage fluid, but not the goblet
cell hyperplasia.
Conclusion: These results suggest that local administration of CD86 siRNA during the effector phase ameliorates
lines of asthma phenotypes. Targeting airway dendritic cells with siRNA suppresses airway inflammation and
hyperresponsiveness in an experimental model of allergic asthma.Background
Interaction of antigen-presenting cells (APCs) and T
cells is crucial in both the initiation and challenge phases
of allergic asthma and, therefore, has possibility as a
target of anti-asthmatic drugs. Optimal T cell activation
and differentiation require not only interaction between
the T cell receptor (TCR) and antigen-MHC complexes
but also interaction between costimulatory ligands on
APCs and their putative receptors on T cells. One of the
best-characterized costimulatory molecules is CD28, which
binds to two costimulatory ligands, B7-1 (CD80) and B7-2
(CD86), on APCs. CD28 is constitutively expressed on both
CD4+ and CD8+T cells. By contrast, CD80/86 expression
on dendritic cells and B cells is upregulated after antigen
pulse in the process of maturating into APCs. Despite* Correspondence: koichi@kokyu.med.kyushu-u.ac.jp
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mediate different mechanisms. CD80 can be more potent
than CD86 in inducing antitumor responses, while CD86
preferentially induces Th2-driven allergic responses [1,2].
It is generally accepted that during APC/T cell interaction,
the B7-CD28 pathway is indispensable for the activation
and differentiation of naïve T cells. However, it remains
controversial whether this pathway has a pivotal role in
the reactivation of primed T cells in the effector phase.
It is well known that the dendritic cell (DC) is the most
powerful APC for inducing allergic immune responses
in vivo. The DC network beneath the epithelium of the
conducting airways is ideally positioned to perform a
surveillance role for inhaled antigens (Ag). By depleting
DCs before the inhaled Ag challenge, all the salient
features of asthma were diminished, and the effector
cytokine secretion was profoundly reduced [3]. More-
over, recent studies suggest that the expression of
CD86, but not CD80, on airway DCs is upregulatedal Ltd. This is an Open Access article distributed under the terms of the Creative
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induces a specific shift in airway DCs from a CD86-low to
a CD86-high phenotype in periphery [4]. Given that lung
DCs maturate and upregulate the expression of CD86
following the allergen challenge [5], it is important to
know whether the upregulation of CD86 has a role in
the development of asthmatic responses.
RNA interference is an endogenous cellular mechanism
in which short interfering RNAs (siRNAs) elicit the
sequence-specific degradation of a complementary mRNA
target. Today, siRNA-mediated gene silencing has become
more powerful, more specific, and much less toxic than
low-molecular-weight chemical inhibitors or blocking
mAbs for laboratory investigations, particularly in vitro. It
is also characterized by a low-cost and transient effect.
Several studies have demonstrated the therapeutic effects
of synthetic siRNA in allergen-induced asthma models
[6-8]. These studies targeted STAT6, TRAIL, and PAI-1,
and the siRNAs were delivered by intratracheal adminis-
tration. Although low transfection efficacy might be a
potential hurdle in RNA interference, it is expected that
DCs can be good targets because of their location and
their prominent particle uptake ability, including the
uptake of short-based nucleotides. Here, we examined
the effects of the downregulation of CD86 by intratracheal
administration of siRNA on Th2 cytokine production in




BALB/c mice were purchased from SLC (Hamamatsu,
Japan). OVA-specific TCR-expressing DO11.10 transgenic
(Tg) mice were provided by Dr. K. Murphy (Washington
University, St. Louis, MO). All experimental procedures
were approved by the animal research ethics committee of
Kyushu University (reference number: A23-048-1).
siRNA preparation
The sequences of the CD86 siRNA were previously deter-
mined by our colleague [9]. siRNAs were synthesized using
Qiagen 2-for-silencing siRNA duplexes (Qiagen, Valencia,
CA). CD86 siRNA has the sequence 5′-CGUUGUGUGU
GUUCUGGAAdTdT-3′ (sense) and 5′-UUCCAGAACAC
ACACAACGdTdT (antisense). As a control, we used single
non-targeting siRNAs.
Transfection
Bone marrow-derived DCs (BMDCs) were obtained as
previously described [10], washed with a serum-free
medium, and cultured in a 24-well tissue culture plate
with 2 × 105 cells/500 μl. Transfection reagent (Gene
Silencer®, Genlantis) and siRNA were added to the wells.
After 4 hours, 500 μl medium with 20% FBS was added.After 24 hours, lipopolysaccharide (LPS) (1 μg/ml; Sigma,
St. Louis, MO, USA) and peptide (p) OVA (C-terminal
323–339 epitope) (5 μg/ml; Bachem, Hauptstrasse,
Switzerland) were added for 18 hours.
Flow cytometry
The cells were stained with FITC-conjugated anti-CD11c
mAb and biotinylated anti-CD86 mAb followed by phyco-
erythrin (PE)-conjugated streptavidin (BD Biosciences).
FITC-conjugated mouse IgG and PE-conjugated IgG were
used as isotype controls. Flow cytometry was performed
on a FACSCalibur flow cytometer equipped with CELL-
Quest software (BD Biosciences). Data was assessed by
mean fluorescent intensity (MFI) or histogram.
Coculture with Th2 cells
CD4+T cells were isolated from the spleens of naïve
DO11.10 mice using magnetic separation (MACS; Miltenyi
Biotec, Bergisch Gladbach, Germany). OVA-specific Th2
cells were induced as previously described [11] and
cultured at a final concentration of 1 × 106 cells/well/
500 μl with siRNA-transfected BMDCs (at 2 × 105 cells/
well/500 μl). The culture supernatants were collected
48 hours later.
Asthma model
BALB/c mice were sensitized with an intraperitoneal
injection of 10 μg OVA (GradeV, Sigma-Aldrich, St. Louis,
MO) with 0.3 mg of Al(OH)3 (SERVA Electrophoresis) on
days 1 and 14. On days 26–28, animals were anesthetized
and treated with intratracheal CD86 siRNA (12.5 μg
siRNA in 50 μl saline). One hour after each treatment, mice
were challenged with aerosolized 1% OVA for 30 minutes.
On day 30, mice were assessed for airway hyperrespon-
siveness (AHR) followed by blood sampling and broncho-
alveolar lavage (BAL) as previously described [12].
Histology
Fresh-frozen sections were prepared with Kawamoto’s
method for maintaining a normal structure [13]. For
fluorescence microscopy, cryosections were stained with
FITC-conjugated anti-CD11c mAb(clone HL3) or FITC-
conjugated anti-CD86 mAb(clone GL1) (BD Biosciences).
Images were acquired using an Olympus (Melville, NY)
BX61 upright microscope. To assess the localization of
siRNA, sensitized mice were intratracheally administrated
Texas Red-labeled siRNA (40 μM/50 μl/animal, siGLO®)
on day 26, followed by the OVA challenge. Twelve hours
after the challenge, cryosections of the tracheas and lungs
were prepared, stained with FITC-labeled anti-CD11c
mAb, and viewed on an A1Rsi confocal laser microscope
(Nikon, Tokyo, Japan). Micrographs were quantitatively
analyzed for the presence of anti-CD86 signals with image
analysis software. For each naïve or control siRNA-treated
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fied. To evaluate only CD86-expressing cells, we selected
an area between the airway epithelium and the lamina
propria mucosae, and counted only dot signals per unit
area. Goblet cell hyperplasia was assessed by staining with
Alcian blue/periodic acid-Schiff (AB/PAS) as described
previously [14].
Determination of MUC5AC mRNA
Total RNA was isolated and quantitative real-time PCR
was conducted for the detection of MUC5AC as described
previously [11].
Measurement of cytokines, chemokine and OVA-specific IgE
Cytokines, chemokine and OVA-specific IgE were quan-
tified using ELISA kits (Invitrogen Corporation or R&D
Systems, Shibayagi for IgE).
Statistical analysis
Values are expressed as the mean (±SEM). Differences
among groups were analyzed using an ANOVA with a
Bonferroni analysis. Nonparametric data were analyzed
using the Mann-Whitney U test. A P value of < .05 was
considered statistically significant.
Results
siRNA downregulates CD86 expression on BMDCs
We first investigated the efficacy of CD86 siRNA in
BMDCs. Immature BMDCs showed moderate expression
of CD86, which was upregulated by maturation-inducing
stimulation with LPS and pOVA for 18 hrs. We compared
the expression level of CD86 between non-targeting
control siRNA-treated and –untreated BMDCs that were
stimulated with LPS and pOVA. There was no significant
difference in CD86 expression (control siRNA-treated
BMDCs, MFI 2593 ± 193; untreated BMDCs, MFI 3065 ±
191; P =0.106 ). We considered that the transfection
protocol per se was neutral in the expression status of
CD86. The expression level of CD86 on CD86 siRNA-
treated BMDCs was significantly lower than that on
non-targeting control siRNA-treated BMDCs [P =0.0014]
(Figure 1). The expression of CD80 was unaffected by
treatment with CD86 siRNA in our preliminary study [9].
These results suggest that treatment with CD86 siRNA
specifically suppresses the activation-induced upregulation
of CD86 on BMDCs in vitro.
CD86 siRNA treatment impairs BMDCs’ ability to activate
Th2 cells
Although many previous studies have shown an essential
role of CD86 on APCs in the antigen priming of naïve T
cells and subsequent Th2 commitment, there have been no
consistent results for the role of CD86 in the reactivation
of antigen-specific Th2 cells. OVA-specific Th2 cellswere induced by coculture of CD4+T cells purified from
the spleens of DO11.10 mice with APCs from the
spleens of naïve BALB/c mice in the presence of pOVA,
recombinant IL-4, neutralizing anti-IL-12 mAb, and
agonistic anti-CD28 mAb, and followed by expansion
with recombinant IL-2 (Figure 2A). Th2 specificity was
confirmed by selective production of IL-4, IL-5, and
IL-13, but to a smaller extent, IFN-γ, which is induced
by coculture of the cells with pOVA-loaded and LPS-
stimulated BMDCs (referred to as pOVA/LPS-BMDCs).
The contents of IL-4, IL-5, and IL-13 in the culture
supernatants from coculture of the cells with CD86
siRNA-treated pOVA/LPS-BMDCs were significantly
lower than those from coculture of the cells with control
siRNA-treated pOVA/LPS-BMDCs [IL-4, P =0.0209; IL-5,
P = 0.0209; IL-13, P =0.0209] (Figure 2B). When BMDCs
were loaded with pOVA but not stimulated with LPS,
almost no Th2 cytokine production was detected (data
not shown). These results suggest that the reactivation
of murine antigen-specific Th2 cells in vitro is partially
dependent on CD86 on APCs.
Intratracheal administration of CD86 siRNA downregulates
CD86 expression in the airway mucosa
In an attempt to assess how intratracheally administrated
siRNA was distributed to the lung, anesthetized mice were
administered with Texas Red-labeled non-coding siRNA
and then challenged with OVA. One hour and 12 hours
after the challenge, frozen sections were made and stained
with FITC-labeled anti-CD11c mAb to detect DCs [15].
One hour after the OVA challenge, Red-labeled siRNA
was detected on the airway epithelial layer in a band-like
deposition pattern. Green-labeled DCs were clustered
around the deposited siRNA (Figure 3A). The immuno-
fluorescence of CD11c+cells in proximity of the red
siRNA signal was observed in several sites per one
section, mainly on the airway epithelial layer. Due to its
characteristic distribution, this was unlikely a sectioning/
deparaffinizing/staining artifact. Twelve hours after the
challenge, the red dots of siRNA were distributed beneath
the airway basement membrane and submucosal DCs,
indicating that siRNA successfully went through the
epithelial barrier (Figure 3B,C). Yellow fluorescence
was observed in several sites, suggestive of siRNA taken
up by DCs, although a mere topological stratification of
fluorescence might not be excluded.
Next, for evaluation of the interfering efficacy, sensitized
mice were intratracheally administered with CD86 siRNA
or control siRNA and given a single challenge with
OVA. Twelve hours after the challenge, the tracheas
and lungs were removed and processed for immune-
fluorescence study. CD86-positive cells were detected by
biotin-conjugated anti-CD86 mAb followed by streptavidin-
conjugated FITC and assessed semi-quantitatively as CD86-
Figure 1 Silencing CD86 expression by transfection with CD86 small interfering RNA (siRNA) on BMDCs. BMDCs were cultured in the
presence of GM-CSF for 7 days. The DCs were transfected with 100nM CD86 siRNA and non-specific (control) siRNA by GeneSilencer®. Twenty-four
hours after gene silencing, DCs were activated with LPS for 18 hours. Cells were stained with FITC-conjugated anti-CD11c mAb and biotinylated
anti-CD86 mAb followed by phycoerithrin (PE)-conjugated streptavidin. CD86 expression on CD11c-positive cells was assessed by flow cytometry.
Histograms represent the number of cells at various fluorescent intensities. MFI data was expressed as the mean ± SEM of 4 mice. * indicates statistically
significant (P <0.05) difference between the indicated two groups.
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the sections of naïve mice, there were scarce CD86-positive
cells in the airway mucosa, although the area of CD86-
positive cells was markedly increased in control siRNA-
treated and OVA-challenged mice. CD86-expressing cells
were detected in dense clusters beneath the airway
epithelium. The upregulation of CD86-positive cells was
significantly suppressed in the CD86 siRNA-treated
mice [P =0.0036]. These results demonstrate that local
administration of siRNA ameliorates the allergen-induced
upregulation of CD86 expression on the airway DCs.CD86 siRNA ameliorates allergen-induced asthma
phenotypes
To examine the effects of pulmonary CD86 inhibition
on asthma phenotypes, CD86 siRNA was administrated
one hour before each OVA challenge (Figures 4 and 5).
Thirty-six hours after the last OVA challenge, airway
hyperresponsiveness to acetylcholine aerosol was mea-
sured. Allergen-induced airway hyperresponsiveness in
CD86 siRNA-treated mice was significantly lower than
that in control siRNA-treated mice [P =0.0432]. The
number of eosinophils in BAL fluid was significantly
Figure 2 Th2 cytokine levels in culture supernatant were analyzed by ELISA. (A) DO11.10 spleen cells were primed with pOVA and APCs
in the presence of rIL-4, anti-IL-12 antibody, CD28, and IL-2. Seven days later, CD4-positive cells were purified using MACS and used as effector
T cells. CD86 siRNA-transfected BMDCs were pulsed with pOVA and stimulated with LPS and then cultured with effector T cells. (B) Coculture
supernatants were collected 48 hours later, and cytokine levels were measured by ELISA (n = 4; mean ± SEM). * indicates statistically significant
(P <0.05) difference between the indicated two groups.
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Figure 3 Distribution of Red-labeled siRNA in the trachea after allergen exposure. Texas Red-labeled siRNA was administrated intratracheally
to sensitized mice. The mice were challenged with OVA 1 hour later. One hour (A) or 12 hours (B) after allergen exposure, lungs are extracted and
stained with DAPI and FITC-conjugated anti-CD11c mAb. Red-labeled siRNA is located in green CD11c-positive cells (arrow).
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siRNA-treated mice [P =0.0117]. The concentrations of
IL-5, IL-13, and CCL17 (TARC [thymus- and activation-
regulated chemokine], in the old nomenclature) in BAL
fluid were significantly lower in CD86 siRNA-treated mice
than in control siRNA-treated mice [IL-4, P = 0.0101; IL-5,
P = 0.0339; IL-13, P =0.0301; CCL17/TARC, P = 0.0479].
The concentration of OVA-specific IgE in the serum was
significantly lower in CD86 siRNA-treated mice than in
control siRNA-treated mice [P =0.0425]. However, the
goblet cell hyperplasia and MUC5AC gene expression were
not significantly different between CD86 siRNA-treated
mice and control siRNA-treated mice (Figure 6). These
results suggest that intratracheal administration of CD86
siRNA effectively ameliorates lines of asthma phenotypes,
except for goblet cell hyperplasia and mucus hyper-
secretion, in a murine model of allergic asthma. In
addition, we confirmed that there was no elevation of
IL-6 and IFN-β in the serum (data not shown) after
CD86 siRNA or control siRNA administration, which
eliminated the possibility that control siRNA or CD86
siRNA administration induced nonspecific inflammation.
Discussion
The present study demonstrated that CD86 siRNA treat-
ment attenuated the upregulation of CD86 on maturing
BMDCs. CD86 siRNA-treated BMDCs were poor stimula-
tors of effector Th2 cells, shown by reduced productions of
IL-4, IL-5, and IL-13, but not of IFN-γ. In vivo, intratracheal
administration of CD86 siRNA during OVA challenge
reduced the production of IL-5, IL-13, and TARC release
and ameliorated airway eosinophilia, airway hyperrespon-
siveness, and elevation of OVA-specific IgE. These results
clearly show that CD86 has a pivotal role in the reactiva-
tion of Th2 cells in the effector phase of allergic reactions.
In addition, CD86 siRNA treatment did not stimulatesystemic production of IL-6 or IFN-β, suggesting that
CD86 may become a promising target for the treatment of
allergic asthma.
The effector phase of allergic reactions has long been
explained by the initiative interaction between antigen-
bearing DCs and a memory phenotype of Th2 cells in
the draining lymph nodes (DLNs). Thus, airway DCs
capture the inhaled allergens, mature with upregulation of
costimulatory molecules, including CD86, and then traffic
into the DLNs, where they meet with antigen-specific
memory Th2 cells. The interaction between those cells
leads to clonal expansion and recirculation of effectory
Th2 cells, leading to recruitment and activation of effector
Th2 cells in the airway mucosa. Although this scenario
might be a rationale to interrupt CD86 to CD28 inter-
action for the treatment of allergic responses, recent
investigations have provided a novel concept regarding
roles of airway DCs in the activation of Th2 in the airway
mucosa. Airway DCs could present antigen directly to
memory Th2 cells in the airway mucosa of OVA-sensitized
and -challenged mice. Of note, this antigen-presenting
activity was accompanied by upregulation of CD86 but
not CD80 [16]. Another study demonstrated that allergic
lungs specifically retained antigen-bearing DCs within the
airway-adjacent region without evidently altering DLN
trafficking [17]. This local presentation pathway may be
a more feasible target of interruption via intra-airway
remedies than is the conventional presentation pathway in
the DLNs. A previous study reported that intraperitoneal
administration of anti-CD86 mAb during OVA challenge
failed to attenuate the subsequent allergic responses in
OVA-sensitized mice [18]. The failure might be explained
by insufficient distribution of anti-CD86 mAb into the
airway mucosa.
Our colleagues have already showed that topical appli-
cation of cream-emulsified CD86 siRNA ameliorated the
Figure 4 Effect of siRNA treatment on CD86 positive cells around airway. Sensitized mice were intratracheally administered with CD86 siRNA
or control siRNA and given a single challenge with OVA. Twelve hours after the challenge, the tracheas and lungs were removed and processed for
immune-fluorescence study. Naïve mice served as negative control. (A) Lung sections from naïve, CD86 siRNA-treated or control siRNA-treated mice
stained with FITC-conjugated anti-CD86 mAb. Bar, 200 μm for upper panel; 100 μm for lower panel. The upper panel and lower panel were obtained
from different mice (B) Micrographs were quantitatively analyzed for the presence of FITC-anti-CD86 signals per unit area with image analysis software.
All data mean ± SEM of 3–4 mice per group. * indicates statistically significant (P <0.05) difference between the indicated two groups.
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and atopic dermatitis-like disease [9]. It also afford col-
lateral evidence that CD86 has a role in effector phase.
But another study reported that intratracheal injection
of OVA-pulsed DCs from CD80/CD86 double-deficient
mice in OVA-sensitized mice led to the reactivation of
Th2 effector responses the same as OVA-pulsed DCs
from wild-type mice [19]. siRNA theoretically causes
ubiquitous gene silencing, leaving a possibility that
CD86 siRNA affects not only airway DCs but also other
cell types. CD86 on alveolar macrophages, eosinophils,
and B cells was reported to play a role in the develop-
ment of allergic airway reactions [20,21]. CD86 on B
cells stimulates CD28 on T cells and transduces positivesignals into B cells that increase IgG1 and IgE produc-
tion. This pathway may be particularly important for
memory B cells in which CD86 is upregulated [22,23].
The reduction of OVA-specific IgE in the serum of
CD86 siRNA-treated mice in the present study is highly
consistent with this pathway.
TARC is the CC chemokine that selectively attracts
Th2 lymphocytes toward APCs [24]. A previous study
showed that TARC expression was highly concentrated
in purified lung DCs [25]. In the present study, the
mechanism remains unclear as to why the concentration
of TARC in BAL fluid was reduced by CD86 siRNA
treatment. We confirmed that CD86 siRNA treatment
per se did not alter the ability to produce TARC in
Figure 5 Effect of treatment with CD86 siRNA on allergic asthmatic response. (A) CD86 siRNA or control siRNA was administrated intratracheally
1 hour before each OVA challenge. (B) Airway hyperresponsiveness to inhaled acetylcholine (ACh) was measured 36 hours after the last OVA
challenge. (C) Cell counts in BAL fluids were performed. Mo = macrophage; Neut = neutrophil; Ly = lymphocyte; Eo = eosinophil. (D) Serum
OVA-IgE levels were analyzed. (E) Cytokine levels and TARC levels in BAL fluids were analyzed. All data mean ± SEM of 8–12 mice per group.
* and † indicate statistically significant (P <0.05) difference between the indicated two groups.
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explanation is that CD86 siRNA treatment reduces recruit-
ment of DCs into the airways by currently unknown
mechanism(s), which results in the reduction of TARC
in the lungs. The quantitative and qualitative assessments
of airway DCs await further investigations.
Contrasting with the effects on lines of asthma pheno-
types, CD86 siRNA treatment failed to ameliorate the gob-
let cell hyperplasia and MUC5AC gene expression, cardinal
features of airway remodeling in asthma. A majority of
asthma phenotypes, including airway eosinophilia, airwayhyperresponsiveness, and airway remodeling, are attribut-
able to the pluripotent effects of IL-13 and its downstream
molecules. Those IL-13-mediated phenotypes vary in
sensitivity to therapeutic interventions. Airway eosinophilia
induced by intratracheal IL-13 was feasibly suppressed by
systemic treatment with glucocorticosteroid, while airway
hyperresponsiveness and remodeling were resistant to
glucocorticosteroid [12]. Similar results were obtained from
our recent study that examined the effect of an inhibitor
of Janus kinase (JAK), a kinase family mediating multiple
cytokine signalings, on OVA-sensitized/challenged mice
Figure 6 Lack of effect of treatment with CD86 siRNA on mucus production in OVA-challenged mice. (A) Lungs were obtained 36 hours
after the last OVA challenge and inflated in formalin. Sections were stained with AB/PAS to identify mucus-containing cells. Representative sections
from naïve, control siRNA, and CD86 siRNA-treated mice are shown. (B) Semi-quantitative analysis of the abundance of PAS-positive cells. The numeric
scores for the abundance of PAS-positive, mucus-containing cells in each airway were determined to be as follows: 0, <5% PAS-positive cells; 1, 5–25%;
2, 25–50%; 3, 50–75%; 4, >75%. (C) MUC5AC expression in mouse whole lung was analyzed by real-time PCR. The relative levels of the MUC5AC
transcripts were presented as fold increase over baseline values. β-actin was taken as a house-keeping gene. All data mean ± SEM of 6–10
mice per group. n.s. means statistically not significant.
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siRNA abolished the OVA-challenge-induced elevation
of IL-13 in BAL fluid, which makes it difficult to explain
the differences in the effects of siRNA via variant sensitiv-
ities of IL-13-mediated asthma phenotypes to therapeutic
interventions. IL-13-independent mechanisms of airway
remodeling must still be elucidated.
To our knowledge, this study is the first report target-
ing airway DCs for treatment with siRNA. The efficient
delivery of siRNA to the target cells has been a challenge
for therapeutic application of siRNA since a majority of
tissue-constructing cells hardly intake a sufficient amount
of siRNA for gene silencing. Given the significant effect
of naked siRNA against CD86 in the present study, vig-
orous phagocytic activity of DCs would be meaningful.
Additional carefully designed studies are required toimprove pharmacokinetics and facilitate cellular uptake
of siRNA [26].
CD86 shares its ligand, CD28, with CD80. In our col-
leagues’ study, freshly isolated murine CD4+T cells were
incubated with murine mastocytoma P815 cells transfec-
tants expressing a similar level of either CD80 or CD86
in the presence of anti-CD3 mAb [27]. Both CD80 and
CD86 costimulated the proliferation of CD4+T cells at
comparable time-kinetics and magnitude, but CD86
alone was able to costimulate IL-4 production in CD4+T
cells. Regarding in vivo models, a previous study showed
that intranasal administration of anti-CD86 mAb markedly
reduced AHR, IgE production, and airway eosinophilia in
OVA-sensitized/challenged mice whereas the treatment
with anti-CD80 reduced airway eosinophilia alone [28].
On the other hand, another study supported a role for
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induced AHR, IgE production, and airway eosinophilia
[29]. In the present study, we selected CD86 as a target
based on the study indicating that T cell activation during
the late-phase airway allergic response is associated with
tracheal DC upregulation of CD86 but not CD80 [16].
Concomitant silencing of CD80 and CD86 is subject to
future investigation.
The limitation of this animal study around interpretation
and translatability to humans may be the choice of OVA
as the allergen compared an allergen more relevant to
humans, and which has intrinsic activity, such as house
dust mite or fungal allergens. Another limitation of this
study to the translatability to human asthma may be the
question of steroids. Inhaled steroid therapy is used as
the mainstay for the treatment of asthma. If steroids
effectively down-regulate CD86, the benefit of CD86
siRNA would be minimal. A previous study showed that
glucocorticoids inhibited the maturation of human DCs
induced by LPS. Thus, glucocorticoids down-regulated
the expression of CD86 following LPS stimulation in vitro
[30]. On the other hand, glucocorticoid insensitivity in
some Th2 clones was reversed by blockade of CD86 to
CD28 signaling in vitro (Dr. Mori A, National Sagamihara
Hospital, Japan, unpublished observation). The relevance
of CD86-targeted approach in various asthma phenotypes
awaits further investigations.
Conclusion
We have shown that local administration of CD86 siRNA
during the effector phase ameliorates lines of asthma
phenotypes. Our study also revealed that reduction of
TARC level in BALF associated in this mechanism. Target-
ing airway dendritic cells with siRNA suppresses airway
inflammation and hyperresponsiveness in an experimental
model of allergic asthma.
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